Prolong Exposure of NSAID in Patients With RA Will Decrease the Risk of Dementia

Abstract

Rheumatoid arthritis (RA), a chronic, systemic inflammatory disorder, primarily affects joints. Several studies have indicated that early inflammation, cardiovascular disease, and depression in patients were associated with a considerably increased risk of dementia. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for treating RA. NSAIDs facilitate alleviating RA-associated chronic pain, inflammation, and swelling. Therefore, we conducted this nationwide study for evaluating the association between the dementia risk and NSAID treatment in patients with RA.The RA cohort comprised patients aged 20 years and older who were newly diagnosed with RA between 2000 and 2011, with data obtained from the Registry of Catastrophic Illnesses Patient Database (RCIPD). Patients without RA were frequency matched with the RA cohort at a 1:4 ratio according to age, sex, and year of RA diagnosis. The relative risks of dementia were estimated using Cox proportional hazard models.The risk of dementia in the RA cohort was not significantly higher than that in the non-RA cohort (adjusted HR [hazard ratio] = 0.95, 95% confidence interval [CI] = 0.87–1.02). Regarding the duration of NSAID treatment, the risk of dementia was significantly lower when the RA cohort used NSAIDs for >2191 days (HR = 0.56, 95% CI = 0.45–0.68).A longer duration of NSAID treatment possibly reduces the risk of dementia. Additional studies are warranted for verifying the association of dementia risk with NSAID treatment in patients with RA.

Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study

“…However, we have tried to use COPD as a proxy variable for cigarette smoking, which has been accepted previously in several studies. [30][31][32][33] Third, the accuracy of diagnoses based on administrative data is another issue of concern.…”

NSAID Exposure and Risk of Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies

“…Several epidemiologic studies showed that patients treated with NSAIDs had a decreased risk for developing AD (Breitner et al, 2009 ; Côté et al, 2012 ; Chang et al, 2016a , b ). However, this evidence was only based on observational studies.…”

Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis

“…In line with this, recent clinical trials have failed to show any positive effect of nonsteroidal anti‐inflammatory drugs (NSAIDs) in individuals at risk for AD . Therefore, the reduced risk of AD among long‐term NSAID users with chronic inflammatory diseases in previous observational studies would suggest a possible positive impact of the specific inflammatory mechanisms (eg, microglia activation) due to the inflammatory disease itself rather than the treatment. Alternatively, suppression of certain aspects of the inflammatory cascade associated with the disease and allowing other aspects to be active could have impacted β‐amyloid deposition.…”